Business Context and Reporting Period
This Form 8-K Current Report is filed by Bionano Genomics, Inc. (BNGO) for the reporting period ending May 28, 2026. The filing addresses a significant corporate event regarding the company's capital structure.
Key Financial Metrics
This filing does not provide specific revenue, profit, cash flow, margin, or liquidity figures. The primary financial metric disclosed is the full repayment of outstanding Senior Secured Convertible Debentures.
- Debt Repayment: All outstanding Senior Secured Convertible Debentures were repaid in full on May 26, 2026.
- Liens and Covenants: All liens on company assets and covenants associated with the Debentures were terminated.
Material Changes
The material change reported is the extinguishment of the company's Senior Secured Convertible Debentures on their scheduled maturity date. This action removes the associated debt obligation and the restrictive covenants and liens previously held against the company's assets.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, updated financial outlook, or specific risk factors beyond the standard disclosure of the debt repayment. The event is presented as a completed transaction with no stated contingencies.
Investor Verification Checklist
- Verify the total principal amount of the Senior Secured Convertible Debentures repaid by reviewing the attached press release (Exhibit 99.1).
- Confirm the source of funds used for the repayment (e.g., cash on hand, new financing, or asset sales) as this is not detailed in the 8-K text.
- Review the impact of the debt extinguishment on the company's balance sheet and future interest expense obligations.
- Check for any remaining debt obligations or covenants not covered by this specific repayment.